Breakthrough Cases

CDC defines a COVID-19 Vaccine Breakthrough Case as a U.S. resident with SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after completing the primary series of an FDA-authorized COVID-19 vaccine. To learn more about breakthrough cases across the U.S. and how they are being reported to the CDC: